{"filing":{"accession_number":"0001171843-26-005010","cik":"0001674632","ticker":"BBNX","company_name":"Beta Bionics, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"f8k_072826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/f8k_072826.htm"},"events":[{"id":21578,"run_id":19465,"accession_number":"0001171843-26-005010","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Beta Bionics issued a press release on July 29, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net sales of $32.0 million (up 38% YoY), gross margin of 59.0%, net loss of $23.4 million, and updated full-year 2026 revenue guidance of $131–$136 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","company_name":"Beta Bionics, Inc.","ticker":"BBNX","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21250,"accession_number":"0001171843-26-005010","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Beta Bionics issued a press release on July 29, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net sales of $32.0 million (up 38% YoY), gross margin of 59.0%, net loss of $23.4 million, and updated full-year 2026 revenue guidance of $131–$136 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:06:06.538734+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21250,"accession_number":"0001171843-26-005010","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Beta Bionics issued a press release on July 29, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net sales of $32.0 million (up 38% YoY), gross margin of 59.0%, net loss of $23.4 million, and updated full-year 2026 revenue guidance of $131–$136 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:06:06.538734+00:00","company_name":"Beta Bionics, Inc.","ticker":"BBNX","filing_date":"2026-07-29"}]}